



## The 65th ASH Annual Meeting Abstracts

## POSTER ABSTRACTS

## 731.AUTOLOGOUS TRANSPLANTATION: CLINICAL AND EPIDEMIOLOGICAL

**Patient Recorded Outcomes from a Randomized, Controlled Phase 2 Trial of E-Selectin Inhibition with Uproleselan Vs Placebo to Reduce GI Toxicity during Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation for Multiple Myeloma**

Meaghan Ryan, NP<sup>1</sup>, Zachary David Crees, MD<sup>2</sup>, Michael Slade, MD<sup>2</sup>, Mark A. Schroeder, MD<sup>2</sup>, Ravi Vij, MD MBA<sup>2</sup>, Geoffrey L Uy, MD<sup>2</sup>, Keith Stockerl-Goldstein, MD<sup>3</sup>

<sup>1</sup>Washington University School of Medicine, Saint Louis, MO

<sup>2</sup>Division of Oncology, Washington University School of Medicine, Saint Louis, MO

<sup>3</sup>Washington University Internal Medicine, Saint Louis, MO

**Background:**

The use of high-dose melphalan conditioning followed by autologous hematopoietic cell transplant (AHCT) continues to be a key component in the treatment of patients with multiple myeloma (MM). However, high-dose melphalan is associated with a high rate of GI toxicity (>90%), which adversely impacts clinical outcomes and negatively influences patient quality of life (QoL). Indeed, it has been reported that AHCT leads to short-term deterioration of health-related QoL in patients with MM, and QoL typically improves by 2-3 months post-AHCT. Pre-clinical and clinical data suggest that E-selectin inhibition may play a role in reducing immune-mediated GI epithelial injury following cytotoxic chemotherapy. We hypothesized that uproleselan (upro), a synthetic, competitive E-selectin antagonist, may improve health-related QoL by reducing risk of chemotherapy-induced diarrhea in patients undergoing AHCT.

**Methods:**

We conducted a Phase 2, single-center, randomized, double-blind, placebo-controlled trial in patients with MM receiving high-dose melphalan (200 mg/m<sup>2</sup>) as conditioning for AHCT for MM. Patients were randomized 1:1 to receive prophylactic upro+standard of care (SoC) vs placebo+SoC. Uproleselan was given in 6 doses of 800 mg IV starting on day-3 through day 0. The primary endpoint was diarrhea severity as assessed by CTCAE v5.0 (secondary endpoint - Bristol Stool Scale). In addition, a key secondary endpoint was patient reported outcomes (PRO) of GI-related QoL using the National Cancer Institute (NCI) PRO-CTCAE Measurement System, a validated PRO tool developed to evaluate symptomatic toxicities in patients with cancer in clinical trials. Significance level of  $p < 0.2$  was pre-specified for all endpoints, per protocol. Patients were surveyed during the peri-transplant period at day-3 (baseline), day+8, and day+14 or day of discharge (DoD). Responses were graded on a scale of 1-5, with 1 indicating absence of symptoms or zero interference with daily activities and 5 indicating very severe symptoms or very significant interference with daily activities. GI-specific domains assessed included swallowing, mouth sores, appetite, nausea, vomiting, heartburn, bloating, abdominal pain, flatulence, and incontinence.

**Results:**


Fifty adult patients with MM were enrolled from 5/2021-10/2022. Baseline PRO symptoms were similar between the upro+SoC and placebo+SoC arms at baseline (day-3). By day+8 post-AHCT patients in the upro+SoC arm reported a significant improvement in severity of GI-related symptoms across 30% (6/20) of domains surveyed vs placebo+SoC ( $p = 0.07-0.14$ ). Furthermore, improvement in mouth sore-related symptoms continued to day+14 post-AHCT in the upro+SoC arm vs placebo+SoC ( $p = 0.17$ ). The remaining GI-related symptoms returned to baseline by D+14 or DoD ( $p > 0.20$ ). Also of note, a numerically lower mean diarrhea severity score and lower incidence of Grade 3 diarrhea (by CTCAE v5.0) was observed favoring upro+SoC which did not meet the pre-specified significance threshold ( $p = 0.34$ ,  $p = 0.26$ , respectively). However, a significant reduction in severe diarrhea (by Bristol Stool Scale) was observed favoring upro+SoC ( $p = 0.10$ ) vs placebo+SoC, with improvement in the upro+SoC arm to mild diarrhea ( $p = 0.02$ ).

**Conclusions:**

Upro+SoC resulted in a clinically significant improvement in GI-toxicity related symptoms as assessed via PRO-CTCAE in patients with MM undergoing melphalan-conditioned AHCT, when compared to placebo+SoC. These improvements in patient reported outcomes are further supported by data from the primary and additional secondary endpoints of the study. Taken together, these results suggest prophylactic E-selectin inhibition may represent a promising strategy to mitigate chemotherapy-

associated GI-toxicity. Further studies are needed to verify these findings and to further define the optimal dosing of upro in the peri-AHCT period.

**Disclosures** **Crees:** *BioLineRx, Ltd.*: Other: Advisory Board, Research Funding. **Slade:** *SecuraBio*: Research Funding. **Schroeder:** *Kura*: Membership on an entity's Board of Directors or advisory committees; *Sorrento therapeutics*: Membership on an entity's Board of Directors or advisory committees; *GSK*: Consultancy; *Incyte*: Honoraria; *Novo nordisk*: Consultancy; *Marker Therapeutics*: Membership on an entity's Board of Directors or advisory committees. **Vij:** *Harpoon*: Honoraria; *Janssen*: Honoraria; *Legend*: Honoraria; *Karyopharm*: Honoraria; *Pfizer*: Honoraria; *Sanofi*: Honoraria, Research Funding; *Takeda*: Honoraria, Research Funding; *Bristol Myers Squibb*: Honoraria, Research Funding. **Uy:** *Jazz*: Other: Advisory Board. **Stockerl-Goldstein:** *Celgene*: Consultancy.



**Figure 1**

<https://doi.org/10.1182/blood-2023-179604>